FDA au­tho­rizes Vir-GSK an­ti­body as vari­ants threat­en Eli Lil­ly mAb

The FDA has au­tho­rized the Covid-19 mon­o­clon­al an­ti­body treat­ment from Vir and Glax­o­SmithK­line, adding an­oth­er po­tent treat­ment op­tion as the pan­dem­ic con­tin­ues to rage in …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER